缬沙坦与卡维地洛对慢性心力衰竭患者的治疗效果

Efficacy of Valsartan and Carvedilol in the Treatment of Patients With Chronic Heart Failure

目的研究缬沙坦联合卡维地洛治疗慢性心力衰竭患者的治疗效果。方法本次数据均来自我院2016年9月—2017年3月接收的90例慢性心力衰竭患者的资料,分成干预组(联合使用缬沙坦与卡维地洛)与常规组(单一使用缬沙坦),每组45人,对比其治疗效果与心功能改善情况。结果干预组总有效率为95.6%;常规组为80.00%;干预组LVEDD、LVEF、LVESD等指标分别为(52.37±5.13)mm、(49.13±4.32)%、(40.07±5.18)mm;常规组分别为(60.14±5.28)mm、(57.92±4.11)%、(45.32±5.29)mm,干预组均优于常规组,差异有统计学意义(P<0.05)。结论在慢性心力衰竭患者的临床治疗中,联合使用缬沙坦和卡维地洛药物不仅具有良好的治疗效果,而且安全性较高。

Objective To study the therapeutic effect of valsartan combined with carvedilol in the treatment of chronic heart failure. Methods From September 2016 to March 2017, 90 patients with chronic heart failure in our hospital were selected, they were divided into intervention group （combination of valsartan and carvedilol） and routine group （single use valsartan）, 45 patients in each group. The effect of the treatment and the improvement of cardiac fimction were compared. Results The total effective rate was 95.6% in the intervention group and 80.00% in the routine group. The indexes of LVEDD, LVEF and LVESD in the intervention group were （52.37±5.13） mm, （49.13±4.32）% and （40.07±5.18） mm, respectively. The routine group was （60.14±5.28） mm, （57.92±4.11）% and （45.32±5.29） ram, respectively. The intervention group was better than the conventional group, and the difference was statistically significant （P 〈 0.05）. Conclusion Valsartan and earvedilol are not only effective in the treatment of chronic heart failure, but also have high safety.